1Joseph A, Vassalotti, Abrigail Falk, et al. The Multidisciplinary Approach to 1.2.4[J]. Journal of Medicine,2004,71(2):94-102.
2Sukbatme VP. Vascular access stenosis : Prospects for prevention and therapy[J]. Kidney Int,1996,49(6): 1161-1174.
3Windus DW. Permanent vascular access: a nephrologist's view[J]. Am J Kidney Dis,1993,21(6):457-471.
4De Marchi S, Ceccin E, Falleti E, et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients[J]. J Am Soc Nephrol,1997, 8(7) :1147-1156.
5Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin [J ]. J Am Soc Nephrol, 1994,4(10) : 1809-1813.
6Crowther MA, Clase CM, Margetts P J, et al. Low-intensity warfarin is ineffctive for the prevention of PTFE graft failure in patients on hemodialysis :a randomized controlled trial[J]. J Am Soc Nephro1,2002,13(9) :2331-2337.
7Kaufan JS, O'connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis [J ]. J Am Soc Nephrol, 2003, 14 (9) :2313-2323.
8Vassalotti JA, Kalk A, Cohl ED, et al. Obese and non-obese hemodialysis patients have a similar prevalence of functioning arteriovenous fistula using pre-operative mapping [J]. Clin Nephrol,2002,58(3) : 211-214.
